The Delhi Excessive Courtroom has allowed Dr. Reddy’s Laboratories to provide any remaining inventory of its semaglutide drug Olymviq to authorities hospitals after the expiry of a 30-day inventory clearance window.
Justice Jyoti Singh formally recorded the settlement between Dr. Reddy’s on Friday, beneath which the Indian pharmaceutical firm will discontinue using the Olymviq identify and transition to a brand new model, Olymra.
The enterprise applies not solely to Dr. Reddy’s but in addition to its administrators, associates and related entities, all of which is able to stop the manufacture, sale, provide, distribution, promotion and any industrial use of the impugned mark, each on-line and offline.
As per the association, Dr. Reddy’s has been permitted to promote its current stock of Olymviq out there for 30 days. Thereafter, any unsold inventory might be equipped to authorities hospitals within the presence of a consultant of Novo Nordisk. Mint reported on 29 March that Dr. Reddy’s would get 30 days to clear its stock after enterprise earlier than the court docket that it could change the model identify and withdraw its trademark functions.
In its written order dated 27 March, earlier reviewed and reported by Mint, the court docket famous that the corporate would withdraw its pending trademark functions for Olymviq from the Commerce Marks Registry, making certain that no additional rights are claimed over the disputed mark.
The court docket clarified that the restricted window for inventory clearance was granted in public curiosity, notably because the drug is utilized by diabetic sufferers. It earlier declined Novo Nordisk’s request for destruction or repackaging of the stock, noting that destroying already manufactured inventory could be detrimental to affected person entry.
The court docket additionally expressed reservations about relabelling, questioning its industrial viability.
Dr. Reddy’s and Novo Nordisk didn’t instantly reply to emails from Mint in search of remark.
Related identify
The dispute stems from a trademark infringement go well with filed by Novo Nordisk, which alleged that Olymviq was deceptively just like its well-known trademark Ozempic, used for its blockbuster semaglutide drug.
Semaglutide, a extensively used therapy for type-2 diabetes and weight administration, is marketed globally by Novo Nordisk beneath the Ozempic, Wegovy and Rybelsus manufacturers. The drug went off-patent in India on 20 March, triggering a wave of lower-cost generic launches by home pharmaceutical corporations, together with Dr. Reddy’s.
Novo argued that Ozempic is a coined and well-known mark with international gross sales exceeding $63 billion over the previous 5 years, and that using comparable names in the identical therapeutic phase may dilute its model and create confusion amongst sufferers and prescribers.
Dr. Reddy’s filed trademark functions for Olymviq in July 2025 and once more in March 2026 and has been engaged in a separate authorized dispute with Novo Nordisk since Could 2025 over alleged infringement of the semaglutide patent.
